Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Immunotherapy for Lung Cancer

Immunotherapy for Lung Cancer News & Analysis News From the Food and Drug Administration Expanded Use of Brain Cancer Device the patients, and the effect lasted between Optune, a portable medical device used to 2.1 and 9.1 months. treat the aggressive brain cancer glioblas- Adverse events from both drugs in- toma multiforme (GBM), has received an ex- cluded fatigue, cough, and decreased appe- panded indication allowing it to be used as tite. In addition, pembrolizumab caused part of standard treatment before the dis- impaired breathing and severe immune- ease progresses (http://1.usa.gov/1jbrVvh). mediatedadverseeffectsinvolvingthelungs, The device initially was approved in 2011 colon, and hormone-producing glands. totreatrecurrenceorprogressionofGBMaf- Nivolumabalsohasthepotentialtocausese- ter chemotherapy. With the expanded indi- vereimmune-mediatedadverseeffects,FDA cation, Optune can be used to treat pa- officials said. tients with newly diagnosed GBM along with the chemotherapy drug temozolomide af- Fast Detection of Central Nervous ter standard treatment that includes sur- System Infections gery and radiation therapy. The device uses A newly approved diagnostic tool is the first nucleic acid–based test capable of quickly electrodes placed directly against the scalp ing to important advances in medicine,” to deliver low-intensity, alternating electri- Richard Pazdur, MD, director of the office of detecting more than 2 dozen pathogens from a small sample http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Immunotherapy for Lung Cancer

JAMA , Volume 314 (19) – Nov 17, 2015

Immunotherapy for Lung Cancer

Abstract

News & Analysis News From the Food and Drug Administration Expanded Use of Brain Cancer Device the patients, and the effect lasted between Optune, a portable medical device used to 2.1 and 9.1 months. treat the aggressive brain cancer glioblas- Adverse events from both drugs in- toma multiforme (GBM), has received an ex- cluded fatigue, cough, and decreased appe- panded indication allowing it to be used as tite. In addition, pembrolizumab caused part of standard treatment before the dis-...
Loading next page...
 
/lp/american-medical-association/immunotherapy-for-lung-cancer-HYIzS3qtKg
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2015.15195
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration Expanded Use of Brain Cancer Device the patients, and the effect lasted between Optune, a portable medical device used to 2.1 and 9.1 months. treat the aggressive brain cancer glioblas- Adverse events from both drugs in- toma multiforme (GBM), has received an ex- cluded fatigue, cough, and decreased appe- panded indication allowing it to be used as tite. In addition, pembrolizumab caused part of standard treatment before the dis- impaired breathing and severe immune- ease progresses (http://1.usa.gov/1jbrVvh). mediatedadverseeffectsinvolvingthelungs, The device initially was approved in 2011 colon, and hormone-producing glands. totreatrecurrenceorprogressionofGBMaf- Nivolumabalsohasthepotentialtocausese- ter chemotherapy. With the expanded indi- vereimmune-mediatedadverseeffects,FDA cation, Optune can be used to treat pa- officials said. tients with newly diagnosed GBM along with the chemotherapy drug temozolomide af- Fast Detection of Central Nervous ter standard treatment that includes sur- System Infections gery and radiation therapy. The device uses A newly approved diagnostic tool is the first nucleic acid–based test capable of quickly electrodes placed directly against the scalp ing to important advances in medicine,” to deliver low-intensity, alternating electri- Richard Pazdur, MD, director of the office of detecting more than 2 dozen pathogens from a small sample

Journal

JAMAAmerican Medical Association

Published: Nov 17, 2015

There are no references for this article.